Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Ong

Showing results (101-110 of 117) with videos related to

Pageof 12
Sort By:
Ethnicity & Disease|September 12, 2018
Comparative Effectiveness of Coalitions Versus Technical Assistance for Depression Quality Improvement in Persons with Multiple Chronic ConditionsBenjamin Springgate, Lingqi Tang, Michael Ong, et al.
Current Oncology (Toronto, Ont.)|May 26, 2026
Forecasting Trends in Androgen Deprivation Therapy Intensification for Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Population-Based Cohort and Time-Series AnalysisEalia Khosh Kish, Erind Dvorani, Refik Saskin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 2, 2019
An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid TumorsRui Wang, Chan Gao, Megan Raymond, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2015
Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug AdministrationJean Sebastien Frenel, Suzanne Carreira, Jane Goodall, et al.
British Journal of Cancer|March 13, 2020
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumoursJohann de Bono, Chia-Chi Lin, Li-Tzong Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2024
Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate CancerEric Winquist, Sebastien J Hotte, Kim Chi, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|February 21, 2024
Addressing controversial areas in the management of advanced prostate cancer in Canada Areas of consensus and controversy from the third Canadian consensus forumFred Saad, Sebastien J Hotte, Krista Noonan, et al.
Future Oncology (London, England)|June 19, 2026
Outcomes of a Canadian real-world cohort of metastatic castration-sensitive prostate cancer patients stratified by early PSA nadirMichael Ong, Christopher Morash, Robert J Hamilton, et al.
European Urology Oncology|July 17, 2019
Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative AnalysisPasquale Rescigno, David Dolling, Vincenza Conteduca, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2014
Antitumor activity in RAS-driven tumors by blocking AKT and MEKAnthony W Tolcher, Khurum Khan, Michael Ong, et al.
Pageof 12

Showing results (101-110 of 117) with videos related to

Sort By:
Pageof 12
Ethnicity & Disease|September 12, 2018
Comparative Effectiveness of Coalitions Versus Technical Assistance for Depression Quality Improvement in Persons with Multiple Chronic ConditionsBenjamin Springgate, Lingqi Tang, Michael Ong, et al.
Current Oncology (Toronto, Ont.)|May 26, 2026
Forecasting Trends in Androgen Deprivation Therapy Intensification for Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Population-Based Cohort and Time-Series AnalysisEalia Khosh Kish, Erind Dvorani, Refik Saskin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 2, 2019
An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid TumorsRui Wang, Chan Gao, Megan Raymond, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2015
Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug AdministrationJean Sebastien Frenel, Suzanne Carreira, Jane Goodall, et al.
British Journal of Cancer|March 13, 2020
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumoursJohann de Bono, Chia-Chi Lin, Li-Tzong Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2024
Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate CancerEric Winquist, Sebastien J Hotte, Kim Chi, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|February 21, 2024
Addressing controversial areas in the management of advanced prostate cancer in Canada Areas of consensus and controversy from the third Canadian consensus forumFred Saad, Sebastien J Hotte, Krista Noonan, et al.
Future Oncology (London, England)|June 19, 2026
Outcomes of a Canadian real-world cohort of metastatic castration-sensitive prostate cancer patients stratified by early PSA nadirMichael Ong, Christopher Morash, Robert J Hamilton, et al.
European Urology Oncology|July 17, 2019
Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative AnalysisPasquale Rescigno, David Dolling, Vincenza Conteduca, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2014
Antitumor activity in RAS-driven tumors by blocking AKT and MEKAnthony W Tolcher, Khurum Khan, Michael Ong, et al.
Pageof 12